New drug combo tested for Tough-to-Treat pancreatic cancer
NCT ID NCT05052723
Summary
This study tested whether combining the drugs cabozantinib and pembrolizumab could help control metastatic pancreatic cancer. It involved 21 patients whose cancer had worsened despite standard treatments. The main goal was to see if the combination could delay cancer growth and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.